Company Overview

We are a clinical stage biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases.

We are applying our proprietary technology platform, Arestat®, to develop a portfolio of proprietary products that address areas of high unmet need in high value markets, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced therapeutics.

 

Latest documents

Proactive Investors interview – Arecor CEO on AT278 partnership with Sequel Med Tech, $11m royalty funding deal and interim result

26 September 2025

Interim results for the six months ended 30 June 2025

26 September 2025

Interim results for the six months ended 30 June 2025

25 September 2025

Contact: ir@arecor.com